{
    "2020-04-30": [
        [
            {
                "time": "",
                "original_text": "【民生医药|点评】康泰生物：销售费用增加影响利润，血制品将处于景气度持续上升趋势",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "销售费用",
                        "利润",
                        "血制品",
                        "景气度"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【民生医药|点评】康泰生物：Q1受疫情影响业绩大幅下滑，在研产品进入收获期 盈利能力下降",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "疫情",
                        "业绩",
                        "在研产品",
                        "盈利能力"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "一季度机构扎堆医药消费科技龙头股",
                "features": {
                    "keywords": [
                        "一季度",
                        "机构",
                        "医药",
                        "消费",
                        "科技",
                        "龙头股"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "消费",
                        "科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【光大医药|年报＆Q1点评】康泰生物：Q1为全年业绩低点，四联苗批签发情况良好",
                "features": {
                    "keywords": [
                        "康泰生物",
                        "年报",
                        "Q1",
                        "业绩",
                        "四联苗",
                        "批签发"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}